Early glycoxidation damage in brains from Down's syndrome.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  1998-02-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/BBRC.1998.8186PMID 9501012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein oxidation and aging

  2006cited by this paper
• An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease

  1997cited by this paper
• Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease

  1997cited by this paper
• Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease.

  1997cited by this paper
• An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease.

  1997cited by this paper
• Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease.

  1997cited by this paper
• RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease

  1996cited by this paper
• RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.

  1996cited by this paper
• Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging

  1996cited by this paper
• Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome

  1996cited by this paper
• Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro

  1995cited by this paper
• Advanced Maillard reaction end products are associated with Alzheimer disease pathology

  1994cited by this paper
• Hydrogen peroxide mediates amyloid beta protein toxicity.

  1994cited by this paper
• Modification of histidine residues in proteins by reaction with 4-hydroxynonenal.

  1992cited by this paper
• Maillard Reaction-Mediated Molecular Damage to Extracellular Matrix and Other Tissue Proteins in Diabetes, Aging, and Uremia

  1992cited by this paper
• Measurement of Malondialdehyde in Plasma by High Performance Liquid Chromatography with Fluorimetric Detection

  1991cited by this paper
• Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal.

  1990cited by this paper
• Degenerative chemistry of malondialdehyde. Structure, stereochemistry, and kinetics of formation of enaminals from reaction with amino acids

  1981cited by this paper
• Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids.

  1980cited by this paper

• Oxidative Stress and Down Syndrome: A Systematic Review

  2025cites this paper
• Increased AGEs/sRAGE ratio and dyslipidemia risk in Down syndrome youths: a cross-sectional study

  2025cites this paper
• Investigating the Origins of Biochemical Dysregulation in Trisomy 21 Pregnancy

  2025cites this paper
• From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach

  2024cites this paper
• Superoxide dismutase and neurological disorders

  2024cites this paper
• Application of regulation of reactive oxygen species and lipid peroxidation to disease treatment

  2022cites this paper
• Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome

  2022cites this paper
• Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope

  2022cites this paper
• Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules

  2021cites this paper
• Mitochondrial Dysfunction in Alzheimer’s Disease: A Biomarker of the Future?

  2021cites this paper
• Use of antioxidants supplementation on developmental outcomes in children with Down Syndrome - a systematic review and meta-analyses.

  2021cites this paper
• Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials

  2020cites this paper
• Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer's disease

  2019cites this paper
• Down Syndrome, Ageing and Epigenetics.

  2019cites this paper
• Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease

  2019cites this paper
• OXIDATIVE DNA DAMAGE AND APOPTOSIS IN DOWN ’ S AND ALZHEIMER ’ S LYMPHOCYTES Ph

  2018cites this paper
• Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

  2016cites this paper
• Investigating The Role Of Dna Polymerase Beta In The Aging Phenotype Of Down Syndrome

  2016cites this paper
• Epigenetic signature in persons with Down Syndrome

  2015cites this paper
• Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

  2015cites this paper
• Down Syndrome as a Special Case of Oxidatively Induced Developmental Dysregulation

  2014cites this paper
• The role of lipid peroxidation in neurological disorders

  2014cites this paper
• Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

  2014cites this paper
• Perinatal and Prenatal Disorders

  2014cites this paper
• Mass spectrometry and redox proteomics: applications in disease.

  2014cites this paper
• Therapeutic potential and structural elucidation of a water-soluble polysaccharide of a wild edible mushroom Agaricus bisporus against neurodegenerative disease, Alzheimer,

  2014cites this paper
• Identification of a DNA methylation signature in blood cells from persons with Down Syndrome

  2014cites this paper
• Unregulated Lipid Peroxidation in Neurological Dysfunction

  2014cites this paper
• Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.

  2013cites this paper
• Markers of neural degeneration and regeneration in Down syndrome patients

  2013cites this paper
• Down syndrome as a model of DNA polymerase beta haploinsufficiency and accelerated aging.

  2012cites this paper
• Down Syndrome: Neuropsychological phenotype and mitochondrial DNA

  2012cites this paper
• Alzheimer's Disease in Down Syndrome.

  2012cites this paper
• Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications

  2012cites this paper
• Down Syndrome: Neuropsychological phenotype and mitochondrial DNA

  2012cites this paper
• Blood markers of oxidative stress in Alzheimer's disease

  2012cites this paper
• Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

  2012cites this paper
• Antioxidants in Down syndrome.

  2012cites this paper
• 4-Hydroxy-2-Nonenal, a Reactive Product of Lipid Peroxidation, and Neurodegenerative Diseases: A Toxic Combination Illuminated by Redox Proteomics Studies

  2012cites this paper
• Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid

  2011cites this paper
• Sweet and sour--oxidative and carbonyl stress in neurological disorders.

  2011cites this paper
• The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

  2011cites this paper
• The identification of protein biomarkers for oxidative stress in Down syndrome

  2011cites this paper
• Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia

  2011cites this paper
• Interaction between 24‐hydroxycholesterol, oxidative stress, and amyloid‐β in amplifying neuronal damage in Alzheimer’s disease: three partners in crime

  2011cites this paper
• Ex vivo detection of histone H1 modified with advanced glycation end products.

  2011cites this paper
• Skeletal Muscle Function, Morphology, and Biochemistry in Ts65Dn Mice: A Model of Down Syndrome

  2011influential citation
• Is antioxidant therapy effective to treat alzheimer's disease?

  2011cites this paper
• Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation

  2011cites this paper
• Die Repression der Translation der anti-amyloidogenen Sekretase ADAM10 durch die 5'-untranslatierte Region

  2010cites this paper
• Mitochondrial Dynamics in Alzheimer’s Disease

  2010cites this paper
• Increased Iron and Free Radical Generation in Preclinical Alzheimer Disease and Mild Cognitive Impairment

  2010cites this paper
• Designing Novel Peptidic Inhibitors of Beta Amyloid Oligomerization

  2010cites this paper
• Oxidative stress in Alzheimer disease: a possibility for prevention.

  2010cites this paper
• 25 Brain Oxidative Stress from a Phospholipid Perspective

  2009cites this paper
• Increased lipid peroxidation in Down’s syndrome mouse models

  2009influential citation
• Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway.

  2009cites this paper
• AGE, ALE, RAGE, and Disease A Food Perspective

  2009cites this paper
• Oxidative Stress Associated Signal Transduction Cascades in Alzheimer Disease

  2009cites this paper
• Involvement of maillard reactions in Alzheimer disease

  2009cites this paper
• Two Hits and You’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease

  2008cites this paper
• Study of cellular responses and protein interactions of Abeta in yeast models

  2008cites this paper
• VLOGA HRANE V GLIKACIJI IN LIPOKSIDACIJI KONČNIH PRODUKTOV IN PRI NASTANKU VNETNIH MEDIATORJEV THE ROLE OF FOOD IN GLYCATION AND LIPOXIDATION OF END PRODUCTS AND - AMPLIFIERS OF INFLAMMATION

  2008cites this paper
• Alzheimer disease, the two-hit hypothesis: an update.

  2007cites this paper
• Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease

  2007cites this paper
• Indices of Metabolic Dysfunction and Oxidative Stress

  2007cites this paper
• Oxidative imbalance in alzheimer’s disease

  2007cites this paper
• Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease

  2007influential citation
• [Advanced glycation and lipoxidation end products--amplifiers of inflammation: the role of food].

  2007cites this paper
• Advanced glycation and lipoxidation end products--amplifiers of inflammation: the role of food.

  2007cites this paper
• Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats.

  2007cites this paper
• Markers of oxidative stress in children with Down syndrome

  2006cites this paper
• Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes.

  2006cites this paper
• Erythrocyte glycohydrolases in subjects with trisomy 21: could Down's syndrome be a model of accelerated ageing?

  2006cites this paper
• Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain.

  2006cites this paper
• Neuropathology of Alzheimer disease: pathognomonic but not pathogenic

  2006cites this paper
• Chronological primacy of oxidative stress in Alzheimer disease.

  2005cites this paper
• Can cognitive deterioration associated with Down syndrome be reduced?

  2005influential citation
• Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases.

  2005cites this paper
• Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.

  2005cites this paper
• Tau phosphorylation in Alzheimer's disease: pathogen or protector?

  2005cites this paper
• Oxidative Adaptation in Aging and Alzheimer’s Disease: The Roles of Amyloid and Tau

  2005cites this paper
• Amyloid- _ and _ in Alzheimer’s Disease: What is the Neuropathology Trying to Tell Us?

  2005cites this paper
• Down's syndrome astrocytes have greater antioxidant capacity than euploid astrocytes

  2004cites this paper
• Homocysteine and Alzheimer's disease: a modifiable risk?

  2004cites this paper
• Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease

  2004cites this paper
• Down syndrome and epilepsy: a nutritional connection?

  2004cites this paper
• Genetic and Toxicological Models of Neurodegenerative Diseases: Stepping Stones Toward Finding a Cure

  2004cites this paper
• Evidence of Oxidative Stress in the Brains of Fetuses with CNS Anomalies and Islet Cell Hyperplasia

  2004cites this paper
• Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part I)

  2003cites this paper
• Molecular changes in fetal Down syndrome brain

  2003cites this paper
• Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia.

  2003cites this paper
• Iron as the malignant spirit in successful ageing.

  2003cites this paper
• Pentosidine and Nε-(carboxymethyl)-lysine in Alzheimer’s disease and vascular dementia

  2003cites this paper
• The Role of Oxidative Imbalance in the Pathogenesis of Down Syndrome

  2003cites this paper
• Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part II)

  2003cites this paper
• Advances in Down Syndrome Research

  2003cites this paper
• Expression of hypothetical proteins in human fetal brain: increased expression of hypothetical protein 28.5kDa in Down syndrome, a clue for its tentative role.

  2003cites this paper
• An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the "gene dosage effect" hypothesis.

  2003cites this paper
• Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer’s disease

  2002cites this paper